Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement

Thrombosis Journal

Volumn 9, Issue , 2011, Pages

  Dranitsaris, George ^a,b   Jelincic, Valentina ^a,b   Choe, Yoonhee ^a,b  

^a Augmentium Pharma Consulting   (Canada)

^b EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; PLACEBO; WARFARIN;

ARTICLE; BLEEDING; DEATH; DRUG EFFICACY; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; META ANALYSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; RISK REDUCTION; SIDE EFFECT; STATISTICAL ANALYSIS; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM;

EID: 79251551379     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-9-3     Document Type: Article

References (33)

1. Weinmann EE, Salzman EW. Deep vein thrombosis. N Engl J Med 1994, 331:1630-41. 10.1056/NEJM199412153312407, 7772110.
2. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007, 13:475-86.
3. Landefeld CS, Ilanus P. Economic burden of venous thromboembolism. Prevention of Venous Thrombosis 1993, 69-85. New York, NY: Marcel Dekker.
4. Geerts WH, Bergqvist D, Pinei GF, et al. Prevention of venous thromboembolism: the 8th Edition ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2008, 133:381S-453S. 10.1378/chest.08-0656, 18574271.
5. Kher A, Samama MM. Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists. J Thromb Haemost 2005, 3:473-81. 10.1111/j.1538-7836.2005.01180.x, 15748236.
6. Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 2009, 27:9-34.
7. Dranitsaris G, Mehta S. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. Appl Health Econ Health Policy 2009, 7:43-59.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
9. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta analyses. BMJ 2003, 327:557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
10. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-101. 10.2307/2533446, 7786990.
11. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 2127453, 9310563.
12. Sutton AJ, Abrams, Jones, Sheldon TA, Song F. Systematic reviews of trials and other studies: Meta regression. Health Tech Assess 1998, 2:81-84.
13. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50:683-691. 10.1016/S0895-4356(97)00049-8, 9250266.
14. Wells G, Sultan SA, Chen L, et al. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. 2009, The Canadian Agency for Drugs and Technologies in Health (CADTH) Report.
15. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326:472. 10.1136/bmj.326.7387.472, 150178, 12609941.
16. Tørholm C, Broeng L, Jørgensen PS, et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. J Bone Joint Surg Br 1991, 73:434-438.
17. Dechavanne M, Ville D, Berruyer M, et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis 1989, 19:5-12.
18. McCart GM, Kayser SR. Therapeutic equivalency of low-molecular-weight heparins. Ann Pharmacother 2002, 36:1042-1057. 10.1345/aph.10264, 12022908.
19. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997, 77:26-31.
20. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty. Thromb Res 1998, 89:281-7. 10.1016/S0049-3848(98)00018-8, 9669750.
21. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs. warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000, 160:2199-2207. 10.1001/archinte.160.14.2199, 10904464.
22. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000, 160:2208-2215. 10.1001/archinte.160.14.2208, 10904465.
23. Turpie AG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986, 315:925-929. 10.1056/NEJM198610093151503, 3531851.
24. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988, 60:407-410.
25. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991, 114:545-551.
26. Colwell CW, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 1994, 76:3-14.
27. Avikainen V, von Bonsdorff H, Partio E, et al. Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement. Ann Chir Gynaecol 1995, 84:85-90.
28. Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996, 335:696-700. 10.1056/NEJM199609053351002, 8703168.
29. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996, 348:224-228. 10.1016/S0140-6736(96)01453-5, 8684199.
30. Rader CP, Kramer C, König A, et al. Low-molecular-weight heparin and partial thromboplastin time-adjusted unfractionated heparin in thromboprophylaxis after total knee and total hip arthroplasty. J Arthroplasty 1998, 13:180-185. 10.1016/S0883-5403(98)90096-1, 9526211.
31. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001, 83:336-345.
32. Senaran H, Acaroǧlu E, Ozdemir HM, et al. Enoxaparin and heparin comparison of deep vein thrombosis prophylaxis in total hip replacement patients. Arch Orthop Trauma Surg 2006, 126:1-5. 10.1007/s00402-005-0079-0, 16333632.
33. Fuji T, Ochi T, Niwa S, et al. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized double-blind placebo-controlled studies with three dosage regimens of enoxaparin. J Orthop Sci 2008, 13:442-451. 10.1007/s00776-008-1264-0, 18843459.